- Home
- STIM vs FT Comparison
STIM vs FT Comparison
Compare STIM & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STIM
- FT
- Stock Information
- Founded
- STIM 2003
- FT 1988
- Country
- STIM United States
- FT United States
- Employees
- STIM N/A
- FT N/A
- Industry
- STIM Medical/Dental Instruments
- FT Trusts Except Educational Religious and Charitable
- Sector
- STIM Health Care
- FT Finance
- Exchange
- STIM Nasdaq
- FT Nasdaq
- Market Cap
- STIM 192.0M
- FT 190.4M
- IPO Year
- STIM 2018
- FT N/A
- Fundamental
- Price
- STIM $4.13
- FT $7.58
- Analyst Decision
- STIM Buy
- FT
- Analyst Count
- STIM 4
- FT 0
- Target Price
- STIM $4.67
- FT N/A
- AVG Volume (30 Days)
- STIM 2.1M
- FT 63.0K
- Earning Date
- STIM 03-04-2025
- FT 01-01-0001
- Dividend Yield
- STIM N/A
- FT 7.85%
- EPS Growth
- STIM N/A
- FT N/A
- EPS
- STIM N/A
- FT N/A
- Revenue
- STIM $72,711,000.00
- FT N/A
- Revenue This Year
- STIM $3.23
- FT N/A
- Revenue Next Year
- STIM $29.55
- FT N/A
- P/E Ratio
- STIM N/A
- FT N/A
- Revenue Growth
- STIM 5.03
- FT N/A
- 52 Week Low
- STIM $0.52
- FT $5.97
- 52 Week High
- STIM $5.07
- FT $7.23
- Technical
- Relative Strength Index (RSI)
- STIM 59.06
- FT 55.22
- Support Level
- STIM $2.80
- FT $7.52
- Resistance Level
- STIM $5.03
- FT $7.65
- Average True Range (ATR)
- STIM 0.49
- FT 0.08
- MACD
- STIM 0.04
- FT -0.01
- Stochastic Oscillator
- STIM 59.64
- FT 59.44
About STIM Neuronetics Inc.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.